Preeclampsia Severe Clinical Trial
Official title:
Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
NCT number | NCT04392375 |
Other study ID # | 2019H0431 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | June 9, 2020 |
Est. completion date | May 10, 2022 |
Verified date | July 2023 |
Source | Ohio State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized double blind placebo controlled trial comparing Nifedipine 30mg XL to placebo in 110 patients after decision has been made to proceed with induction of labor for the diagnosis of preeclampsia with severe features.
Status | Completed |
Enrollment | 110 |
Est. completion date | May 10, 2022 |
Est. primary completion date | April 20, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria. - Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures. Exclusion Criteria: - Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder. - Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor - Participation in another trial that affects the primary outcome without prior approval - Physician/provider or patient refusal - Participation in this trial in a prior pregnancy - Triplet or higher order pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo | Measured acute antihypertension therapy between enrollment and delivery | Between enrollment and delivery, assessed up to 18 weeks | |
Secondary | Number of Participants Stratified by Route of Delivery | At delivery | ||
Secondary | Number of Participants With Various Indications for Cesarean Delivery | Some participants could have more than one indication for Cesarean Delivery. | Between enrollment and delivery, assessed up to 18 weeks | |
Secondary | Number of Participants With Hypotension of =30% Decrease in Blood Pressure From Baseline Following Acute Antihypertensive Therapy | Between enrollment and delivery, assessed up to 18 weeks | ||
Secondary | Number of Participants Who Required Acute Antihypertension Treatments Postpartum | At delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04243278 -
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
|
Early Phase 1 | |
Not yet recruiting |
NCT03318211 -
Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT05594056 -
Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia.
|
N/A | |
Recruiting |
NCT03761888 -
Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
|
||
Not yet recruiting |
NCT06373367 -
Preeclampsia Educational Program Study (PrEPS)
|
N/A | |
Not yet recruiting |
NCT04855513 -
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
|
N/A | |
Not yet recruiting |
NCT05232994 -
Metformin and Esomeprazole For Preterm Pre-eclampsia
|
Phase 1 | |
Recruiting |
NCT03978767 -
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
|
Phase 2 | |
Completed |
NCT04236258 -
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
|
Phase 4 | |
Completed |
NCT04756661 -
Uterotonics for Severe Preeclampsia
|
N/A | |
Active, not recruiting |
NCT04660032 -
Nudge to Drive Transitions of Care
|
N/A | |
Completed |
NCT04103489 -
The Use of Eculizumab in HELLP Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT04794855 -
Risk Prediction Model of Preeclampsia
|
||
Recruiting |
NCT04311749 -
Expanded NIPT for Pregnancy Complications
|
||
Active, not recruiting |
NCT06359015 -
Metformin and Esomeprazole in Preterm Pre-eclampsia
|
Phase 4 | |
Recruiting |
NCT05610774 -
Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine
|
N/A | |
Completed |
NCT03815110 -
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
|
||
Completed |
NCT03210350 -
Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
|
||
Completed |
NCT03451266 -
Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia
|
Phase 1 | |
Active, not recruiting |
NCT06360601 -
Intravenous Labetalol Versus Hydralazine in Preeclampsia
|
Phase 1/Phase 2 |